Boehringer Ingelheim Corporation's Investigational Faldaprevir+ Achieved Viral Cure in 88% of Treatment-Naive Hepatitis C Patients in Asia

Published: Jun 10, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

INGELHEIM, Germany--(BUSINESS WIRE)--New findings presented today during the APASL Liver Week in Singapore, highlighted the efficacy and safety of faldaprevir+ plus pegylated interferon and ribavirin (PegIFN/RBV) in treatment-naïve patients with genotype-1 hepatitis C virus (HCV) in Asia.1 This post-hoc sub-analysis of the Phase III STARTVerso™1 and 2 trials showed that both doses of faldaprevir were associated with high viral cure rates and a shorter treatment duration in this particular patient group.1 The STARTVerso™1 and 2 trials are part of the global STARTVerso™ trial programme which includes four Phase III trials with more than 2,200 treatment-naïve, treatment-experienced and HIV co-infected patients with HCV.2,3,4,5

Help employers find you! Check out all the jobs and post your resume.

Back to news